Disease Landscape and Forecast Insights

Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. Physicians address this risk with various lipid-modifying therapies…

Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. To address this risk factor, physicians use a range of lipid-modifying…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds…

Dyslipidemia is an important modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading causes of death globally. Statins continue to dominate treatment for dyslipidemia,…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key dyslipidemia patient populations covering 171 countries and more…

Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD), which is primarily managed by statin therapy. With positive CV outcomes data for certain nonstatin therapies including…